BioCentury | Jun 8, 2015
Company News

Alseres, Navidea deal

...in Phase III testing for early detection of Parkinson’s disease (see BioCentury, Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...radiopharmaceutical used with SPECT imaging that binds to dopamine transporter sites in the brain, from Alseres Pharmaceuticals Inc....
BioCentury | Jun 2, 2014
Company News

Navidea diagnostic news

...a partner or once cash flow increases. Navidea has exclusive, worldwide rights to NAV5001 from Alseres Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

Altropane: Phase III started

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Sep 2, 2013
Clinical News

Altropane: SPA received

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Therafectin amiprilose Hcl data

...is adequate to sustain current R&D plans through 1999. The Therafectin trial cost $3.5 million. Boston Life...
BioCentury | Apr 8, 2013
Clinical News

Altropane: Clinical trial started

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Aug 6, 2012
Company News

Alseres, Navidea deal

...deal to license exclusive, worldwide rights to develop and commercialize imaging agent Altropane from Alseres. Alseres...
...based on Navidea's close of $4.09 on July 30, before the finalized deal was announced. Alseres...
...for $2.9 million in milestone payments and an additional 1.2 million shares of Navidea stock. Alseres...
BioCentury | Jul 2, 2012
Company News

Alseres, Navidea deal

...$250,000 payment to Alseres. Under the terms of the license, if Navidea exercises the option, Alseres...
...the brain, is in Phase III testing as an aid in diagnosing Parkinson's disease (PD). Alseres Pharmaceuticals Inc....
BioCentury | Jan 30, 2012
Company News

Alseres, Navidea deal

...Navidea an option to license exclusive, worldwide rights to imaging agent Altropane by June 30. Alseres...
...the license agreement. Under the preliminary terms of the license, if Navidea exercises the option, Alseres...
...the brain, is in Phase III testing as an aid in diagnosing Parkinson's disease (PD). Alseres Pharmaceuticals Inc....
Items per page:
1 - 10 of 160
BioCentury | Jun 8, 2015
Company News

Alseres, Navidea deal

...in Phase III testing for early detection of Parkinson’s disease (see BioCentury, Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...radiopharmaceutical used with SPECT imaging that binds to dopamine transporter sites in the brain, from Alseres Pharmaceuticals Inc....
BioCentury | Jun 2, 2014
Company News

Navidea diagnostic news

...a partner or once cash flow increases. Navidea has exclusive, worldwide rights to NAV5001 from Alseres Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

Altropane: Phase III started

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Sep 2, 2013
Clinical News

Altropane: SPA received

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Therafectin amiprilose Hcl data

...is adequate to sustain current R&D plans through 1999. The Therafectin trial cost $3.5 million. Boston Life...
BioCentury | Apr 8, 2013
Clinical News

Altropane: Clinical trial started

...develop and commercialize NAV5001 from Alseres (see BioCentury, Jan. 30, 2012 & Aug. 6, 2012). Alseres Pharmaceuticals Inc....
BioCentury | Aug 6, 2012
Company News

Alseres, Navidea deal

...deal to license exclusive, worldwide rights to develop and commercialize imaging agent Altropane from Alseres. Alseres...
...based on Navidea's close of $4.09 on July 30, before the finalized deal was announced. Alseres...
...for $2.9 million in milestone payments and an additional 1.2 million shares of Navidea stock. Alseres...
BioCentury | Jul 2, 2012
Company News

Alseres, Navidea deal

...$250,000 payment to Alseres. Under the terms of the license, if Navidea exercises the option, Alseres...
...the brain, is in Phase III testing as an aid in diagnosing Parkinson's disease (PD). Alseres Pharmaceuticals Inc....
BioCentury | Jan 30, 2012
Company News

Alseres, Navidea deal

...Navidea an option to license exclusive, worldwide rights to imaging agent Altropane by June 30. Alseres...
...the license agreement. Under the preliminary terms of the license, if Navidea exercises the option, Alseres...
...the brain, is in Phase III testing as an aid in diagnosing Parkinson's disease (PD). Alseres Pharmaceuticals Inc....
Items per page:
1 - 10 of 160